In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk.
Where this comes from
- Record sourced from PubMed, PMID 37665995.
- Also identified by DOI 10.7326/J23-0069.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Loftus EV Jr, Panés J, Lacerda AP, et al. <b>Upadacitinib induction and maintenance therapy for Crohn's disease.</b> N Engl J Med. 2023;388:1966-1980. 37224198.
Medical subject headings
- Crohn Disease